Rapid Exploratory Imaging for High-resolution and Whole Extremity Coverage in MR Neurography
Dr. Olivier Scheidegger, Inselspital Bern
Abstract (Lay summary see below)
Magnetic resonance (MR) imaging of peripheral nerves, termed MR neurography (MRN), is increasingly gaining attention for clinical diagnostic evaluation and treatment monitoring of peripheral nerve diseases. It allows morphologic investigation of proximal and deeply situated nerve segments not accessible by other diagnostic techniques. MR neurography is now clinically used as a complementary tool to electrodiagnostic studies, and allows quantification of biophysical nerve tissue properties based on morphology and signal behaviour. Previously, we have developed a fully automatic nerve segmentation technique for clinical MRN images using convolutional neural networks (artificial intelligence, deep learning) and proposed a concept of quantitative analysis of nerve morphology and lesion type. Using even higher resolution MRN, qualitative analysis of nerve substructures such as nerve fascicle bundles becomes now available. However, these MRN sequences are 2-D sequences, require long acquisition times (1-2 hours for an entire extremity), and are prone to motion artifacts, limiting their extended use despite their potential of shedding new insights into nerve pathology. The aim of this project is to develop a completely new MRN sequence termed ”rapid exploratory imaging (REI)” for motion-insensitive, 3-D high-resolution imaging (down to 200-250 micrometers) that can cover a whole extremity from the nerve roots to the most distal parts within a clinical feasible scan time of around 20 minutes. The REI sequence development will follow a single slab 3-D turbo spin echo sequence with variable excitation pulses to restrain specific-absorption-rate issues. State-ofthe-art fat saturation schemes shall be applied in the REI sequence to improve image contrast. To achieve our aims of high resolution and fast acquisition times, non-Cartesian acquisition schemes combined with parallel imaging and compressed sensing reconstruction algorithms will be used. Complex iterative algorithms based on non-uniform fast Fourier transform will be employed for MR signal reconstruction, adopting variable artificial intelligence for near real-time results. Quantitative morphometric analysis of peripheral nerves will be performed using an adoption of our previous work using fully-convolutional neural networks (AI) in a prospective study of clinically and neurophysiologically defined patient cohort. This project is a straightforward corollary of our previous work and builds on a fruitful collaboration with biomedical engineers and physicists at the University of Bern and the Institute of Myology in Paris.
Lay summary
“Rapid Exploratory Imaging (REI)” - Eine neue hochaufgelöste MR Neurographie Technik für die Bildgebung peripherer Nerven
Die Diagnostik von Nervenschädigungen beruht auf der ärztlichen Untersuchung sowie neurophysiologischer Messungen der Nerven und Muskeln an Armen und Beinen. Nerven nahe der Wirbelsäule lassen sich so nur schlecht untersuchen. In den letzten Jahren hat sich als zusätzliche Abklärungsmethode die hochauflösende MR Neurographie etabliert, welche eine bildgebende Darstellung auch kleiner Strukturen innerhalb der Nerven ermöglicht. Leider ist diese Technik sehr zeitintensiv und nur auf kleine Nervenabschnitte beschränkt. Ziel dieses Projektes ist es, eine neue MR Pulssequenz zu entwickeln (“REI”), welche Nervenstrukturen in 3D in einer Auflösung von ca. 250 Mikrometer ermöglicht, und dies über grosse Nervenabschnitte und in einer kurzen Aufnahmezeit. Die Schwierigkeit besteht insbesondere darin, dass die Aufarbeitung des MR-Signals und die Bildanalyse im weiteren Verlauf selbst aufgrund der grossen Datenmenge sehr komplex ist. Mittels Einsatzes künstlicher Intelligenz soll diese Datenverarbeitung möglich sein.
Projekte
- Neue Forschungsprojekte ab 2024
- Die Bedeutung und die Erfolge der Forschung
- Finanzierte Projekte
- Unstructured proteins as therapeutic targets for neuromuscular diseases
- Open and reproducible pipeline for the acquisition and analysis of muscle MRI data in Facioscapulohumeral Muscular Dystrophy
- Dissecting lysosomal signals to fight Pompe disease
- Functional properties and epigenetic signature of quiescent and early activated human muscle reserve cells
- Activation of human skeletal muscle stem cells:role of Orai3 ans its partner AHNAK2 in physiological condition and in Duchenne Muscular Dystrophy
- Understanding the clinical spectrum associated with VMA21 deficiency
- ANTXR2 as a key player in Collagen VI signaling in muscle stem cells: new therapeutic perspectives for COL6-related myopathies.
- Molecular mechanisms of complement activation and neuromuscular disruption by combinations of autoantibodies from patients with Myasthenia Gravis
- From the investigation of the role of SRSF1 in ALS/FTD to its targeting as a therapeutic strategy
- Molecular crosstalk between muscles and motor neurons and its role in neuromuscular circuit formation
- Molecular Diagnosis and Coping Mechanisms in Mitochondrial Myopathies
- IPRIMYO: Immune-privileged, immortal, myogenic stem cells for gene therapy of Muscular Dystrophy
- Effect of RYR1 mutations on muscle spindle function and their impact on the musculoskeletal system
- Therapeutic potential of human myogenic reserve cells in Duchenne Muscular Dystrophy
- Glutamine metabolism as a potential target for Duchenne Muscular Dystrophy
- Targeting protein s-acylation during Tubular Aggregate Myopathy
- Aggravating the phenotype of dystrophic mice for improving preclinical research and clinical translation for Duchenne muscular dystrophy
- Characterization of autoreactive T cells in Guillain-Barré syndrome
- A vascularized human muscle-on-a-chip to elucidate the contribution of endothelial-mesenchymal transition on the progression of muscular dystrophies
- Characterization of a novel form of ALS associated with changes in the sphingolipid metabolism
- Pre-clinical treatment of mouse models carrying recessive Ryr1 mutations with HDAC/DNA methyltransferase inhibitors.
- New aspects of TGFβ signaling in muscle homeostasis and regeneration
- Inhibition of sphingolipid synthesis as a treatment strategy for Duchenne muscular dystrophy
- Tamoxifen in Duchenne muscular dystrophy (TAMDMD)
- DNA aptamers against the DUX4 protein reveal novel therapeutic implications for FSHD
- Facilitating diagnosis of critical illness myopathy using muscle excitability testing
- Rapid Exploratory Imaging for High-resolution and Whole Extremity Coverage in MR Neurography
- Deciphering novel mechanisms and effectors contributing to muscle dysfunction in Myotonic Dystrophy Type I
- Can HDAC/DNA methyltransferase inhibitors improve muscle function in a congenital myopathy caused by recessive RYR1 mutations?
- Identification of the critical regulators of protein synthesis and degradation in human muscle atrophy
- Exploring peripheral B-cell-helper T cell phenotypes in the blood of patients with Myasthenia gravis using mass cytometry (CyTOF)
- Molecular signature, metabolic profile and therapeutic potential of human myogenic reserve cells
- A multicenter cross-sectional and longitudinal study of the Swiss cohort of Merosin-negative congenital muscular dystrophy
- Targeting NADPH oxidase 4 in models of Duchenne muscular dystrophy
- Characterizing the role of ER stress in C9orf72-linked ALS pathology
- Inducing mitophagy with Urolithin A to restore mitochondrial and muscle function in muscular dystrophy
- Motor unit action potentials analysis in patients with myopathies with a new wireless portable and multichannel Surface EMG device (WPM-SEMG)
- Role and therapeutic potential of PLIN3 in neuromuscular diseases
- Changes in ventilation distribution in children with neuromuscular disease using the insufflator/exsufflator technique: An observational study
- Mechanism and function of genome organization in muscle development and integrity
- Role and therapeutic potential of NADPH oxidases in a mouse model of Duchenne Muscular Dystrophy
- Characterization of pathological pathways activated in muscles of patients with congenital myopathies with disturbed Ca2+ homeostasis
- Creation of a study team to conduct an SMA 1-clinical trial at the Centre for Neuromuscular Diseases of the University Children's Hospital Basel (UKBB)
- Novel treatment to stop progressive neuropathy and muscle weakness in multifocal motor neuropathy
- Understanding the pathomechanisms leading to muscle alterations in Myotonic Dystrophy type I
- Automated volumetry and quantitative MRI to diagnose peripheral nerve lesions – translational proposal for a new clinical diagnostic imaging tool
- Novel approaches against Spinal Muscular Atrophy by targeting splicing regulators
- Protective effects and mechanisms of action of tamoxifen in mice with severe muscular diseases
- Role of the receptor FgfrL1 in the development of slow muscle fibers
- Muscle velocity recovery cycles: A new tool for early diagnosis of critical illness myopathy
- Generation of uncommitted human IPSC derived muscle stem cells for therapeutic applications
- Transposable vectors for dystrophin-expression in a murine model for muscular dystrophy
- Cardiac involvement in patients with Duchenne/Becker Muscular Dystrophy; an observational study
- Deciphering the pathogenic mechanisms of C9ORF72 ALS
- Enhancing estrogenic signalling to fight muscular dystrophies: Mechanisms of action and repurposing clinically approved drugs
- Mechanisms and therapeutic potential of modulating PGC‐1α to alter neuromuscular junction morphology and function
- Triggering human myoblast differentiation: from EGFR to myogenic transcription factors
- Improving cellular therapies of muscle dystrophies by uncovering epigenetic and signaling pathways of muscle formation
- Protein engineering in an attempt to increase the mechanical, integrin dependent cytoskeleton-matrix linkage in muscle fibers
- Muscle velocity recovery cycles: a new tool for characterization of muscle disease in vivo
- Excessive neurotrypsin activation and agrin cleavage-a pathogenic condition leading to sarcopenia-like muscle atrophy?
- Evaluation of novel treatment strategies for dyspherlinopathies in mouse models
- Cell therapy of LGMD2D by donor HLA-characterized human mesoangioblasts (hMABs) produced in GMP conditions
- In search of small molecules targeting protein-RNA complex: a novel approach against Spinal Muscular Atrophy
- Restoration of autophagy as a new strategy for the treatment of congenital muscular dystrophies
- Development of magnetic resonance methods for functional imaging of the skeletal muscle
- Targeting ER stress response: a potential mechanism for neuroprotection in Amyotrophic Lateral Sclerosis
- Generation of uncommitted human IPSC derived muscle stem cells for therapeutic applications
- Projektbroschüre
- SEAL Therapeutics AG
- Meetings und Seminare
- Teilnahme an Dachverbände
- Patientenregister
- Netzwerk Myosuisse
FSRMM
- Chemin des Saules 4B
2013 Colombier - +41 78 629 63 92
- philippe.rognon@fsrmm.ch